A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
A Study Of GW679769 Compared To Placebo In Women With Overactive Bladder
This is a Phase IIa study to evaluate the efficacy, safety and tolerability of GW679769 vs
 placebo on symptoms of urgency with urge incontinence, frequency and nocturia associated with
 overactive bladder in women.
A Twelve-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Forced Titration,
 Proof of Concept Study to Assess the Efficacy, Safety and Tolerability as well as the
 Pharmacokinetic Profile of 60 mg and 120 mg of GW679769 administered once daily vs Placebo in
 Women with Overactive Bladder
Inclusion Criteria:

 -  Female subjects with overactive bladder with symptoms of urgency with urge
 incontinence and frequency which may be associated with nocturia but without bladder
 pain.

 -  Must not be pregnant.

 -  Must not be of childbearing potential or is willing to use specific barrier methods
 outlined in the protocol.

 -  Body weight in the range of = 45 kg and <100 kg.

 Exclusion Criteria:

 -  Stage III/IV pelvic organ prolapse with or without cystocele.

 -  History of interstitial cystitis or bladder related pain.

 -  Subjects with stress incontinence or mixed incontinence where stress incontinence is
 the predominant component based on prior history.

 -  History of pelvic prolapse repair (cystocele or rectocele) or urethral
 diverticulectomy within six months of screening.

 -  Subjects with urinary incontinence due to causes other then detrusor over activity
 (e.g., overflow incontinence).

 -  Nocturnal enuresis only.

 -  Urinary retention, or other evidence of poor detrusor function.

 -  History of prior anti-incontinence surgery.

 -  History of radiation cystitis or a history of pelvic irradiation.

 -  Electrostimulation, biofeedback, or bladder training therapy (behavioral therapy)
 during the previous month prior to screening, or the intention to initiate such
 therapies during the study. Pessaries and implants are also excluded.

 -  Participated in any clinical trial of an investigation drug that may affect urinary
 function within 3 months of enrollment into the study.

 -  Received any investigational product within 30 days of enrollment into the study.